Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
LFW Photonics Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Kala Pharmaceuticals, Inc.
Kala Pharmaceuticals Announces Name Change to KALA BIO
August 02, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 19, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 23, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 02, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 09, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED
April 28, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect
April 12, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor
March 29, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED
March 27, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 08, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 03, 2023
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED
December 27, 2022
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect
November 28, 2022
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing
November 28, 2022
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 08, 2022
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors
November 01, 2022
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Announces Reverse Stock Split
October 20, 2022
From
Kala Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
KALA
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
June 18, 2021
From
Kala Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALA
Kala Pharmaceuticals Announces EYSUVIS® Now Covered by OptumRx
June 03, 2021
From
Kala Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALA
Kala Pharmaceuticals to Present at Jefferies 2021 Virtual Healthcare Conference
May 27, 2021
From
Kala Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALA
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
May 20, 2021
From
Kala Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALA
Kala Pharmaceuticals to Present at BofA Securities 2021 Healthcare Conference
May 06, 2021
From
Kala Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALA
Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 05, 2021
From
Kala Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALA
Kala Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call
April 28, 2021
From
Kala Pharmaceuticals, Inc.
Via
Business Wire
Tickers
KALA
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.